In this report, Fior Markets covers the present scenario (with the base year being 2017) and the growth prospects of global Drugs for Vulvovaginal Candidiasis market for 2018-2023.
The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.
Some women with recurrent candidal infections opt for treatment with over-the-counter (OTC) medications, which generally are highly effective for candidiasis. Preparations for intravaginal administration of butoconazole, clotrimazole, miconazole, and tioconazole are available OTC.
The classification of Drugs for Vulvovaginal Candidiasis includes Cream, Pessary and other. The proportion of Cream in 2017 is about 47.2%, and the proportion of Pessary in 2017 is about 34.1%.
The drugs for Vulvovaginal Candidiasis are Miconazole, Clotrimazole, Fluconazole, Econazole and Other, market share of Fluconazole is about 24.5% in 2017.
Drugs for Vulvovaginal Candidiasis is application in Hospital & Clinic and Pharmacy. The most of Drugs for Vulvovaginal Candidiasis is used in Pharmacy, and the market share in 2016 is about 59%.
Over the next five years, Fior Markets projects that Drugs for Vulvovaginal Candidiasis will register a 2.1% CAGR in terms of revenue, reach US$ 870 million by 2023, from US$ 770 million in 2017.
This report presents a comprehensive overview, market shares, and growth opportunities of Drugs for Vulvovaginal Candidiasis market by product type, application, key manufacturers and key regions.
To calculate the market size, Fior Markets considers value and volume generated from the sales of the following segments:
Segmentation by product type:
Cream
Pessary
Other
Segmentation by application:
Hospital & Clinic
Pharmacy
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report:
Bayer
Perrigo
J & J
Pfizer
Bristol-Myers Squibb
Effik
Teva
Sanofi
Cisen Pharmaceutical
Kingyork Group
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Drugs for Vulvovaginal Candidiasis consumption (value & volume) by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.
To understand the structure of Drugs for Vulvovaginal Candidiasis market by identifying its various subsegments.
Focuses on the key global Drugs for Vulvovaginal Candidiasis manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Drugs for Vulvovaginal Candidiasis with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Drugs for Vulvovaginal Candidiasis submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
Table of Contents
2018-2023 Global Drugs for Vulvovaginal Candidiasis Consumption Market Report
1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Economic Indicators
1.6 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Drugs for Vulvovaginal Candidiasis Consumption 2013-2023
2.1.2 Drugs for Vulvovaginal Candidiasis Consumption CAGR by Region
2.2 Drugs for Vulvovaginal Candidiasis Segment by Type
2.2.1 Cream
2.2.2 Pessary
2.2.3 Other
2.3 Drugs for Vulvovaginal Candidiasis Consumption by Type
2.3.1 Global Drugs for Vulvovaginal Candidiasis Consumption Market Share by Type (2013-2018)
2.3.2 Global Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Type (2013-2018)
2.3.3 Global Drugs for Vulvovaginal Candidiasis Sale Price by Type (2013-2018)
2.4 Drugs for Vulvovaginal Candidiasis Segment by Application
2.4.1 Hospital & Clinic
2.4.2 Pharmacy
2.5 Drugs for Vulvovaginal Candidiasis Consumption by Application
2.5.1 Global Drugs for Vulvovaginal Candidiasis Consumption Market Share by Application (2013-2018)
2.5.2 Global Drugs for Vulvovaginal Candidiasis Value and Market Share by Application (2013-2018)
2.5.3 Global Drugs for Vulvovaginal Candidiasis Sale Price by Application (2013-2018)
3 Global Drugs for Vulvovaginal Candidiasis by Players
3.1 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Players
3.1.1 Global Drugs for Vulvovaginal Candidiasis Sales by Players (2016-2018)
3.1.2 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Players (2016-2018)
3.2 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Players
3.2.1 Global Drugs for Vulvovaginal Candidiasis Revenue by Players (2016-2018)
3.2.2 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Players (2016-2018)
3.3 Global Drugs for Vulvovaginal Candidiasis Sale Price by Players
3.4 Global Drugs for Vulvovaginal Candidiasis Manufacturing Base Distribution, Sales Area, Product Types by Players
3.4.1 Global Drugs for Vulvovaginal Candidiasis Manufacturing Base Distribution and Sales Area by Players
3.4.2 Players Drugs for Vulvovaginal Candidiasis Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2016-2018)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 Drugs for Vulvovaginal Candidiasis by Regions
4.1 Drugs for Vulvovaginal Candidiasis by Regions
4.1.1 Global Drugs for Vulvovaginal Candidiasis Consumption by Regions
4.1.2 Global Drugs for Vulvovaginal Candidiasis Value by Regions
4.2 Americas Drugs for Vulvovaginal Candidiasis Consumption Growth
4.3 APAC Drugs for Vulvovaginal Candidiasis Consumption Growth
4.4 Europe Drugs for Vulvovaginal Candidiasis Consumption Growth
4.5 Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption Growth
5 Americas
5.1 Americas Drugs for Vulvovaginal Candidiasis Consumption by Countries
5.1.1 Americas Drugs for Vulvovaginal Candidiasis Consumption by Countries (2013-2018)
5.1.2 Americas Drugs for Vulvovaginal Candidiasis Value by Countries (2013-2018)
5.2 Americas Drugs for Vulvovaginal Candidiasis Consumption by Type
5.3 Americas Drugs for Vulvovaginal Candidiasis Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Key Economic Indicators of Few Americas Countries
6 APAC
6.1 APAC Drugs for Vulvovaginal Candidiasis Consumption by Countries
6.1.1 APAC Drugs for Vulvovaginal Candidiasis Consumption by Countries (2013-2018)
6.1.2 APAC Drugs for Vulvovaginal Candidiasis Value by Countries (2013-2018)
6.2 APAC Drugs for Vulvovaginal Candidiasis Consumption by Type
6.3 APAC Drugs for Vulvovaginal Candidiasis Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Countries
7 Europe
7.1 Europe Drugs for Vulvovaginal Candidiasis by Countries
7.1.1 Europe Drugs for Vulvovaginal Candidiasis Consumption by Countries (2013-2018)
7.1.2 Europe Drugs for Vulvovaginal Candidiasis Value by Countries (2013-2018)
7.2 Europe Drugs for Vulvovaginal Candidiasis Consumption by Type
7.3 Europe Drugs for Vulvovaginal Candidiasis Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
8.1 Middle East & Africa Drugs for Vulvovaginal Candidiasis by Countries
8.1.1 Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption by Countries (2013-2018)
8.1.2 Middle East & Africa Drugs for Vulvovaginal Candidiasis Value by Countries (2013-2018)
8.2 Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption by Type
8.3 Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends
10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.2 Drugs for Vulvovaginal Candidiasis Distributors
10.3 Drugs for Vulvovaginal Candidiasis Customer
11 Global Drugs for Vulvovaginal Candidiasis Market Forecast
11.1 Global Drugs for Vulvovaginal Candidiasis Consumption Forecast (2018-2023)
11.2 Global Drugs for Vulvovaginal Candidiasis Forecast by Regions
11.2.1 Global Drugs for Vulvovaginal Candidiasis Forecast by Regions (2018-2023)
11.2.2 Global Drugs for Vulvovaginal Candidiasis Value Forecast by Regions (2018-2023)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.5.6 Spain Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Drugs for Vulvovaginal Candidiasis Forecast by Type
11.8 Global Drugs for Vulvovaginal Candidiasis Forecast by Application
12 Key Players Analysis
12.1 Bayer
12.1.1 Company Details
12.1.2 Drugs for Vulvovaginal Candidiasis Product Offered
12.1.3 Bayer Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2016-2018)
12.1.4 Main Business Overview
12.1.5 Bayer News
12.2 Perrigo
12.2.1 Company Details
12.2.2 Drugs for Vulvovaginal Candidiasis Product Offered
12.2.3 Perrigo Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2016-2018)
12.2.4 Main Business Overview
12.2.5 Perrigo News
12.3 J & J
12.3.1 Company Details
12.3.2 Drugs for Vulvovaginal Candidiasis Product Offered
12.3.3 J & J Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2016-2018)
12.3.4 Main Business Overview
12.3.5 J & J News
12.4 Pfizer
12.4.1 Company Details
12.4.2 Drugs for Vulvovaginal Candidiasis Product Offered
12.4.3 Pfizer Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2016-2018)
12.4.4 Main Business Overview
12.4.5 Pfizer News
12.5 Bristol-Myers Squibb
12.5.1 Company Details
12.5.2 Drugs for Vulvovaginal Candidiasis Product Offered
12.5.3 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2016-2018)
12.5.4 Main Business Overview
12.5.5 Bristol-Myers Squibb News
12.6 Effik
12.6.1 Company Details
12.6.2 Drugs for Vulvovaginal Candidiasis Product Offered
12.6.3 Effik Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2016-2018)
12.6.4 Main Business Overview
12.6.5 Effik News
12.7 Teva
12.7.1 Company Details
12.7.2 Drugs for Vulvovaginal Candidiasis Product Offered
12.7.3 Teva Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2016-2018)
12.7.4 Main Business Overview
12.7.5 Teva News
12.8 Sanofi
12.8.1 Company Details
12.8.2 Drugs for Vulvovaginal Candidiasis Product Offered
12.8.3 Sanofi Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2016-2018)
12.8.4 Main Business Overview
12.8.5 Sanofi News
12.9 Cisen Pharmaceutical
12.9.1 Company Details
12.9.2 Drugs for Vulvovaginal Candidiasis Product Offered
12.9.3 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2016-2018)
12.9.4 Main Business Overview
12.9.5 Cisen Pharmaceutical News
12.10 Kingyork Group
12.10.1 Company Details
12.10.2 Drugs for Vulvovaginal Candidiasis Product Offered
12.10.3 Kingyork Group Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2016-2018)
12.10.4 Main Business Overview
12.10.5 Kingyork Group News
13 Research Findings and Conclusion
Copyright © 2019 Fior Market Research LLP, All Rights Reserved.